Wellington Management Group
CRVS icon

Wellington Management Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Wellington Management Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8M Buy
2,731,632
+413,115
+18% +$5.73M 0.01% 812
2026
Q1 		$33.9M Buy
2,318,517
+2,003,834
+637% +$32M 0.01% 848
2025
Q4 		$2.42M Buy
314,683
+134,508
+75% +$1.06M ﹤0.01% 1553
2025
Q3 		$1.33M Buy
180,175
+77,828
+76% +$398K ﹤0.01% 1719
2025
Q2 		$409K Sell
102,347
-2,525
-2% -$9.19K ﹤0.01% 1847
2025
Q1 		$333K Buy
+104,872
New +$494K ﹤0.01% 1865

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Wellington Management Group's CRVS Position: Q2 2026 in Review

Wellington Management Group increased its Corvus Pharmaceuticals (CRVS) stake by 18% in Q2 2026, buying an estimated $5.73M and bringing the position to 2,731,632 shares worth $40.8M. The position accounts for 0.01% of the portfolio, ranked #812.

Wellington Management Group first reported a position in CRVS in Q1 2025 and has held it in 6 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Wellington Management Group held 2,731,632 shares of Corvus Pharmaceuticals worth $40.8M as of Q2 2026.
  • Wellington Management Group bought 413,115 Corvus Pharmaceuticals shares in Q2 2026, an estimated $5.73M.
  • Corvus Pharmaceuticals made up 0.01% of Wellington Management Group's portfolio in Q2 2026, its #812 holding.
  • Wellington Management Group first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.